Share Price and Basic Stock Data
Last Updated: October 29, 2025, 9:33 pm
| PEG Ratio | 0.05 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Nath Bio-Genes (India) Ltd operates in the seeds, tissue culture, and biotechnology industry, with a current market capitalization of ₹321 Cr. The company’s stock price stood at ₹169, reflecting a price-to-earnings (P/E) ratio of 7.01, indicating a potentially undervalued position compared to sector averages. Over the past fiscal years, Nath Bio-Genes has demonstrated a fluctuating revenue trend, with sales reported at ₹234 Cr for the year ending March 2023, marginally increasing to ₹248 Cr for March 2024. The trailing twelve months (TTM) sales reached ₹399 Cr, showcasing a robust growth trajectory. Quarterly sales figures reveal significant seasonal variations, with the highest sales recorded in June 2025 at ₹280 Cr. However, the company faces challenges with low quarterly sales in certain months, such as ₹22 Cr in September 2022, which raises concerns over revenue consistency.
Profitability and Efficiency Metrics
The profitability of Nath Bio-Genes is characterized by a reported net profit of ₹48 Cr, translating to a net profit margin of 10.57% for the fiscal year ending March 2025. The operating profit margin (OPM) stood at 14% for the same period, reflecting efficiency in managing operational costs. However, the company experienced fluctuations in quarterly performance, with the OPM dipping to a low of 6% in March 2025. Return on equity (ROE) recorded at 6.77% and return on capital employed (ROCE) at 7.35% indicate moderate returns relative to the overall capital invested. The cash conversion cycle (CCC) of 122 days suggests room for improvement in working capital management, as the industry norm typically ranges between 90 to 100 days. Consequently, while profitability metrics exhibit potential, the efficiency ratios highlight areas that require strategic enhancements.
Balance Sheet Strength and Financial Ratios
Nath Bio-Genes maintains a relatively stable balance sheet, with total assets reported at ₹1,017 Cr, against total liabilities of ₹1,017 Cr, indicating a balanced financial structure. The company’s reserves stood at ₹630 Cr, providing a strong buffer for future investments and operational needs. Borrowings have increased slightly to ₹111 Cr, but the low debt-to-equity ratio of 0.19 suggests a conservative approach to leveraging. The interest coverage ratio (ICR) of 5.18x reflects the company’s ability to meet interest obligations comfortably. Additionally, the price-to-book value (P/BV) ratio of 0.43x indicates that the stock is trading at a discount relative to its book value, which might attract value-focused investors. However, the current ratio of 1.89x suggests adequate liquidity, while the quick ratio of 0.96x indicates potential liquidity challenges in meeting short-term obligations.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Nath Bio-Genes reveals a significant public ownership at 51.73%, with promoters holding 45.59% of the equity. This distribution demonstrates a healthy level of public participation, potentially enhancing liquidity and investor confidence. Foreign institutional investors (FIIs) have increased their stake to 0.41%, up from 0.01% in September 2022, indicating growing interest from global investors. Conversely, domestic institutional investors (DIIs) have seen a decline in their holdings, dropping to 2.25% by March 2025. The total number of shareholders stood at 34,207, reflecting a stable investor base. However, the decline in DII participation could signal concerns among institutional players regarding the company’s growth prospects or market conditions. Overall, the shareholding structure supports a stable governance environment, although the shifting dynamics among institutional investors warrant attention.
Outlook, Risks, and Final Insight
Nath Bio-Genes faces a mixed outlook characterized by both strengths and risks. The company’s solid revenue growth, evidenced by the TTM figure of ₹399 Cr, and its low P/E ratio suggest potential for capital appreciation. However, the fluctuating quarterly sales and profitability margins highlight risks related to revenue consistency and operational efficiency. The high cash conversion cycle indicates potential liquidity challenges that could hinder growth if not managed effectively. Furthermore, the declining DII participation could reflect broader market apprehensions. To navigate these challenges, Nath Bio-Genes must focus on stabilizing revenue streams and optimizing operational efficiencies while maintaining prudent financial management. If the company can enhance its operational metrics and capitalize on its market position, it may see improved investor confidence and sustained growth in the coming years.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Nath Bio-Genes (India) Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Genomic Valley Biotech Ltd | 9.09 Cr. | 29.8 | 108/27.2 | 90.9 | 12.8 | 0.00 % | 11.8 % | 9.68 % | 10.0 |
| Genesis IBRC India Ltd | 201 Cr. | 155 | 155/15.8 | 57.8 | 6.56 | 0.00 % | 51.6 % | 51.6 % | 10.0 |
| Shreeoswal Seeds & Chemicals Ltd | 141 Cr. | 15.4 | 24.5/10.7 | 10.4 | 4.78 | 0.00 % | 9.88 % | 8.41 % | 2.00 |
| Nath Bio-Genes (India) Ltd | 321 Cr. | 169 | 239/138 | 7.00 | 341 | 1.18 % | 7.35 % | 6.77 % | 10.0 |
| Continental Seeds and Chemicals Ltd | 24.5 Cr. | 22.2 | 48.8/20.8 | 41.5 | 25.8 | 0.00 % | 4.24 % | 2.87 % | 10.0 |
| Industry Average | 221.00 Cr | 78.28 | 41.52 | 78.19 | 0.24% | 16.97% | 15.87% | 8.40 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 209 | 22 | 25 | 45 | 235 | 23 | 32 | 43 | 244 | 32 | 37 | 49 | 280 |
| Expenses | 175 | 17 | 20 | 41 | 198 | 17 | 26 | 39 | 207 | 26 | 29 | 46 | 241 |
| Operating Profit | 34 | 5 | 6 | 4 | 37 | 5 | 6 | 4 | 37 | 7 | 8 | 3 | 39 |
| OPM % | 16% | 22% | 22% | 9% | 16% | 23% | 18% | 10% | 15% | 20% | 20% | 6% | 14% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 0 | 0 | 5 | 4 |
| Interest | 3 | 3 | 3 | 2 | 3 | 2 | 3 | 1 | 2 | 3 | 3 | 1 | 3 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 31 | 2 | 2 | 2 | 34 | 2 | 5 | 4 | 34 | 3 | 4 | 5 | 39 |
| Tax % | 1% | 4% | 34% | 13% | 1% | 18% | 16% | 16% | 1% | -1% | 30% | 12% | 2% |
| Net Profit | 31 | 1 | 1 | 2 | 33 | 2 | 4 | 3 | 34 | 3 | 3 | 5 | 38 |
| EPS in Rs | 16.19 | 0.77 | 0.71 | 0.84 | 17.58 | 0.85 | 2.08 | 1.69 | 17.83 | 1.52 | 1.40 | 2.48 | 20.11 |
Last Updated: August 1, 2025, 4:35 pm
Below is a detailed analysis of the quarterly data for Nath Bio-Genes (India) Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 280.00 Cr.. The value appears strong and on an upward trend. It has increased from 49.00 Cr. (Mar 2025) to 280.00 Cr., marking an increase of 231.00 Cr..
- For Expenses, as of Jun 2025, the value is 241.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 46.00 Cr. (Mar 2025) to 241.00 Cr., marking an increase of 195.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 39.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2025) to 39.00 Cr., marking an increase of 36.00 Cr..
- For OPM %, as of Jun 2025, the value is 14.00%. The value appears strong and on an upward trend. It has increased from 6.00% (Mar 2025) to 14.00%, marking an increase of 8.00%.
- For Other Income, as of Jun 2025, the value is 4.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5.00 Cr. (Mar 2025) to 4.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 3.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.00 Cr. (Mar 2025) to 3.00 Cr., marking an increase of 2.00 Cr..
- For Depreciation, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 39.00 Cr.. The value appears strong and on an upward trend. It has increased from 5.00 Cr. (Mar 2025) to 39.00 Cr., marking an increase of 34.00 Cr..
- For Tax %, as of Jun 2025, the value is 2.00%. The value appears to be improving (decreasing) as expected. It has decreased from 12.00% (Mar 2025) to 2.00%, marking a decrease of 10.00%.
- For Net Profit, as of Jun 2025, the value is 38.00 Cr.. The value appears strong and on an upward trend. It has increased from 5.00 Cr. (Mar 2025) to 38.00 Cr., marking an increase of 33.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 20.11. The value appears strong and on an upward trend. It has increased from 2.48 (Mar 2025) to 20.11, marking an increase of 17.63.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:47 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 136 | 143 | 127 | 142 | 171 | 206 | 246 | 271 | 230 | 234 | 248 | 265 | 399 |
| Expenses | 102 | 109 | 103 | 113 | 131 | 163 | 191 | 204 | 193 | 185 | 197 | 212 | 342 |
| Operating Profit | 34 | 35 | 25 | 29 | 40 | 43 | 55 | 67 | 37 | 49 | 50 | 53 | 56 |
| OPM % | 25% | 24% | 19% | 20% | 24% | 21% | 22% | 25% | 16% | 21% | 20% | 20% | 14% |
| Other Income | 1 | 1 | 1 | 0 | 1 | 2 | 2 | 2 | -87 | 1 | 4 | 4 | 9 |
| Interest | 4 | 5 | 6 | 10 | 10 | 5 | 7 | 9 | 11 | 10 | 9 | 10 | 10 |
| Depreciation | 5 | 4 | 4 | 3 | 1 | 1 | 1 | 3 | 3 | 3 | 3 | 4 | 4 |
| Profit before tax | 26 | 26 | 15 | 17 | 30 | 39 | 49 | 57 | -63 | 36 | 42 | 44 | 51 |
| Tax % | 5% | 4% | 6% | 3% | 2% | 1% | -4% | 2% | 6% | 3% | 5% | 4% | |
| Net Profit | 24 | 25 | 14 | 16 | 29 | 38 | 50 | 56 | -67 | 35 | 40 | 42 | 48 |
| EPS in Rs | 15.18 | 15.87 | 8.85 | 10.17 | 15.48 | 20.22 | 26.56 | 29.29 | -35.43 | 18.51 | 21.14 | 22.17 | 25.51 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 7% | -6% | 11% | 9% | 9% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 4.17% | -44.00% | 14.29% | 81.25% | 31.03% | 31.58% | 12.00% | -219.64% | 152.24% | 14.29% | 5.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -48.17% | 58.29% | 66.96% | -50.22% | 0.54% | -19.58% | -231.64% | 371.88% | -137.95% | -9.29% |
Nath Bio-Genes (India) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 2% |
| 3 Years: | 5% |
| TTM: | 17% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | -3% |
| 3 Years: | 21% |
| TTM: | 17% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | -10% |
| 3 Years: | -1% |
| 1 Year: | -22% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 7% |
| 3 Years: | 6% |
| Last Year: | 7% |
Last Updated: September 5, 2025, 11:35 am
Balance Sheet
Last Updated: May 13, 2025, 3:02 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 16 | 16 | 19 | 19 | 19 | 19 | 19 | 19 | 19 | 19 |
| Reserves | 66 | 91 | 105 | 287 | 450 | 489 | 539 | 594 | 523 | 554 | 592 | 630 |
| Borrowings | 23 | 22 | 59 | 74 | 33 | 58 | 70 | 101 | 93 | 105 | 108 | 111 |
| Other Liabilities | 85 | 97 | 87 | 78 | 69 | 80 | 102 | 75 | 105 | 114 | 158 | 257 |
| Total Liabilities | 190 | 226 | 267 | 455 | 571 | 646 | 730 | 790 | 740 | 793 | 877 | 1,017 |
| Fixed Assets | 17 | 13 | 30 | 207 | 211 | 232 | 246 | 247 | 245 | 244 | 249 | 250 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 6 |
| Other Assets | 168 | 208 | 231 | 243 | 355 | 409 | 479 | 538 | 490 | 544 | 622 | 761 |
| Total Assets | 190 | 226 | 267 | 455 | 571 | 646 | 730 | 790 | 740 | 793 | 877 | 1,017 |
Below is a detailed analysis of the balance sheet data for Nath Bio-Genes (India) Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 19.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 19.00 Cr..
- For Reserves, as of Mar 2025, the value is 630.00 Cr.. The value appears strong and on an upward trend. It has increased from 592.00 Cr. (Mar 2024) to 630.00 Cr., marking an increase of 38.00 Cr..
- For Borrowings, as of Mar 2025, the value is 111.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 108.00 Cr. (Mar 2024) to 111.00 Cr., marking an increase of 3.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 257.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 158.00 Cr. (Mar 2024) to 257.00 Cr., marking an increase of 99.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 1,017.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 877.00 Cr. (Mar 2024) to 1,017.00 Cr., marking an increase of 140.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 250.00 Cr.. The value appears strong and on an upward trend. It has increased from 249.00 Cr. (Mar 2024) to 250.00 Cr., marking an increase of 1.00 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 6.00 Cr..
- For Other Assets, as of Mar 2025, the value is 761.00 Cr.. The value appears strong and on an upward trend. It has increased from 622.00 Cr. (Mar 2024) to 761.00 Cr., marking an increase of 139.00 Cr..
- For Total Assets, as of Mar 2025, the value is 1,017.00 Cr.. The value appears strong and on an upward trend. It has increased from 877.00 Cr. (Mar 2024) to 1,017.00 Cr., marking an increase of 140.00 Cr..
Notably, the Reserves (630.00 Cr.) exceed the Borrowings (111.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 11.00 | 13.00 | -34.00 | -45.00 | 7.00 | -15.00 | -15.00 | -34.00 | -56.00 | -56.00 | -58.00 | -58.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 95 | 114 | 130 | 133 | 175 | 191 | 159 | 147 | 136 | 152 | 139 | 122 |
| Inventory Days | 3,840 | 4,743 | 4,388 | |||||||||
| Days Payable | 1,309 | 1,406 | 586 | |||||||||
| Cash Conversion Cycle | 95 | 114 | 130 | 2,665 | 3,512 | 191 | 159 | 147 | 136 | 3,954 | 139 | 122 |
| Working Capital Days | 126 | 190 | 259 | 273 | 447 | 442 | 416 | 450 | 427 | 416 | 343 | 316 |
| ROCE % | 33% | 26% | 14% | 10% | 9% | 8% | 9% | 10% | 5% | 7% | 7% | 7% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Aditya Birla Sun Life Pure Value Fund | 828,595 | 0.32 | 16.53 | 828,595 | 2025-04-22 15:56:55 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 13 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 19.85 | 19.52 | 18.43 | -35.55 | 7.34 |
| Diluted EPS (Rs.) | 19.85 | 19.52 | 18.43 | -35.55 | 7.34 |
| Cash EPS (Rs.) | 22.32 | 22.56 | 20.01 | -33.84 | 10.16 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 339.08 | 320.94 | 301.60 | 285.16 | 35.91 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 339.08 | 320.94 | 301.60 | 285.16 | 35.91 |
| Revenue From Operations / Share (Rs.) | 192.02 | 175.03 | 158.58 | 146.47 | 86.04 |
| PBDIT / Share (Rs.) | 28.60 | 26.57 | 25.94 | 20.54 | 12.80 |
| PBIT / Share (Rs.) | 26.59 | 24.85 | 24.36 | 18.92 | 9.98 |
| PBT / Share (Rs.) | 21.36 | 21.87 | 19.03 | -33.38 | 7.68 |
| Net Profit / Share (Rs.) | 20.31 | 20.85 | 18.42 | -35.46 | 7.34 |
| NP After MI And SOA / Share (Rs.) | 20.31 | 20.85 | 18.42 | -35.46 | 7.34 |
| PBDIT Margin (%) | 14.89 | 15.17 | 16.35 | 14.02 | 14.87 |
| PBIT Margin (%) | 13.84 | 14.19 | 15.35 | 12.91 | 11.59 |
| PBT Margin (%) | 11.12 | 12.49 | 12.00 | -22.78 | 8.92 |
| Net Profit Margin (%) | 10.57 | 11.91 | 11.61 | -24.20 | 8.52 |
| NP After MI And SOA Margin (%) | 10.57 | 11.91 | 11.61 | -24.20 | 8.52 |
| Return on Networth / Equity (%) | 5.99 | 6.49 | 6.10 | -12.43 | 20.43 |
| Return on Capital Employeed (%) | 7.64 | 7.64 | 8.03 | 6.59 | 26.54 |
| Return On Assets (%) | 3.76 | 4.50 | 4.41 | -9.11 | 7.42 |
| Long Term Debt / Equity (X) | 0.02 | 0.01 | 0.00 | 0.00 | 0.02 |
| Total Debt / Equity (X) | 0.19 | 0.18 | 0.18 | 0.17 | 0.31 |
| Asset Turnover Ratio (%) | 0.38 | 0.39 | 0.39 | 0.00 | 1.05 |
| Current Ratio (X) | 1.89 | 2.18 | 2.41 | 2.41 | 1.22 |
| Quick Ratio (X) | 0.96 | 1.30 | 1.45 | 1.27 | 0.43 |
| Inventory Turnover Ratio (X) | 1.28 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 9.84 | 9.59 | 10.85 | -5.64 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 8.96 | 8.86 | 9.99 | -5.91 | 0.00 |
| Earning Retention Ratio (%) | 90.16 | 90.41 | 89.15 | 105.64 | 0.00 |
| Cash Earning Retention Ratio (%) | 91.04 | 91.14 | 90.01 | 105.91 | 0.00 |
| Interest Coverage Ratio (X) | 5.18 | 5.54 | 4.87 | 3.68 | 5.58 |
| Interest Coverage Ratio (Post Tax) (X) | 4.63 | 4.97 | 4.46 | 3.02 | 4.20 |
| Enterprise Value (Cr.) | 310.77 | 363.13 | 336.48 | 494.22 | 0.00 |
| EV / Net Operating Revenue (X) | 0.85 | 1.09 | 1.12 | 1.78 | 0.00 |
| EV / EBITDA (X) | 5.72 | 7.19 | 6.83 | 12.66 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 0.75 | 0.99 | 0.89 | 1.46 | 0.00 |
| Retention Ratios (%) | 90.15 | 90.40 | 89.14 | 105.64 | 0.00 |
| Price / BV (X) | 0.43 | 0.54 | 0.46 | 0.74 | 0.00 |
| Price / Net Operating Revenue (X) | 0.75 | 0.99 | 0.89 | 1.46 | 0.00 |
| EarningsYield | 0.13 | 0.11 | 0.13 | -0.16 | 0.00 |
After reviewing the key financial ratios for Nath Bio-Genes (India) Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 19.85. This value is within the healthy range. It has increased from 19.52 (Mar 24) to 19.85, marking an increase of 0.33.
- For Diluted EPS (Rs.), as of Mar 25, the value is 19.85. This value is within the healthy range. It has increased from 19.52 (Mar 24) to 19.85, marking an increase of 0.33.
- For Cash EPS (Rs.), as of Mar 25, the value is 22.32. This value is within the healthy range. It has decreased from 22.56 (Mar 24) to 22.32, marking a decrease of 0.24.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 339.08. It has increased from 320.94 (Mar 24) to 339.08, marking an increase of 18.14.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 339.08. It has increased from 320.94 (Mar 24) to 339.08, marking an increase of 18.14.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 192.02. It has increased from 175.03 (Mar 24) to 192.02, marking an increase of 16.99.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 28.60. This value is within the healthy range. It has increased from 26.57 (Mar 24) to 28.60, marking an increase of 2.03.
- For PBIT / Share (Rs.), as of Mar 25, the value is 26.59. This value is within the healthy range. It has increased from 24.85 (Mar 24) to 26.59, marking an increase of 1.74.
- For PBT / Share (Rs.), as of Mar 25, the value is 21.36. This value is within the healthy range. It has decreased from 21.87 (Mar 24) to 21.36, marking a decrease of 0.51.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 20.31. This value is within the healthy range. It has decreased from 20.85 (Mar 24) to 20.31, marking a decrease of 0.54.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 20.31. This value is within the healthy range. It has decreased from 20.85 (Mar 24) to 20.31, marking a decrease of 0.54.
- For PBDIT Margin (%), as of Mar 25, the value is 14.89. This value is within the healthy range. It has decreased from 15.17 (Mar 24) to 14.89, marking a decrease of 0.28.
- For PBIT Margin (%), as of Mar 25, the value is 13.84. This value is within the healthy range. It has decreased from 14.19 (Mar 24) to 13.84, marking a decrease of 0.35.
- For PBT Margin (%), as of Mar 25, the value is 11.12. This value is within the healthy range. It has decreased from 12.49 (Mar 24) to 11.12, marking a decrease of 1.37.
- For Net Profit Margin (%), as of Mar 25, the value is 10.57. This value exceeds the healthy maximum of 10. It has decreased from 11.91 (Mar 24) to 10.57, marking a decrease of 1.34.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 10.57. This value is within the healthy range. It has decreased from 11.91 (Mar 24) to 10.57, marking a decrease of 1.34.
- For Return on Networth / Equity (%), as of Mar 25, the value is 5.99. This value is below the healthy minimum of 15. It has decreased from 6.49 (Mar 24) to 5.99, marking a decrease of 0.50.
- For Return on Capital Employeed (%), as of Mar 25, the value is 7.64. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 7.64.
- For Return On Assets (%), as of Mar 25, the value is 3.76. This value is below the healthy minimum of 5. It has decreased from 4.50 (Mar 24) to 3.76, marking a decrease of 0.74.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.19. This value is within the healthy range. It has increased from 0.18 (Mar 24) to 0.19, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.38. It has decreased from 0.39 (Mar 24) to 0.38, marking a decrease of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 1.89. This value is within the healthy range. It has decreased from 2.18 (Mar 24) to 1.89, marking a decrease of 0.29.
- For Quick Ratio (X), as of Mar 25, the value is 0.96. This value is below the healthy minimum of 1. It has decreased from 1.30 (Mar 24) to 0.96, marking a decrease of 0.34.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.28. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 1.28, marking an increase of 1.28.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 9.84. This value is below the healthy minimum of 20. It has increased from 9.59 (Mar 24) to 9.84, marking an increase of 0.25.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 8.96. This value is below the healthy minimum of 20. It has increased from 8.86 (Mar 24) to 8.96, marking an increase of 0.10.
- For Earning Retention Ratio (%), as of Mar 25, the value is 90.16. This value exceeds the healthy maximum of 70. It has decreased from 90.41 (Mar 24) to 90.16, marking a decrease of 0.25.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 91.04. This value exceeds the healthy maximum of 70. It has decreased from 91.14 (Mar 24) to 91.04, marking a decrease of 0.10.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.18. This value is within the healthy range. It has decreased from 5.54 (Mar 24) to 5.18, marking a decrease of 0.36.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.63. This value is within the healthy range. It has decreased from 4.97 (Mar 24) to 4.63, marking a decrease of 0.34.
- For Enterprise Value (Cr.), as of Mar 25, the value is 310.77. It has decreased from 363.13 (Mar 24) to 310.77, marking a decrease of 52.36.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.85. This value is below the healthy minimum of 1. It has decreased from 1.09 (Mar 24) to 0.85, marking a decrease of 0.24.
- For EV / EBITDA (X), as of Mar 25, the value is 5.72. This value is within the healthy range. It has decreased from 7.19 (Mar 24) to 5.72, marking a decrease of 1.47.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.75. This value is below the healthy minimum of 1. It has decreased from 0.99 (Mar 24) to 0.75, marking a decrease of 0.24.
- For Retention Ratios (%), as of Mar 25, the value is 90.15. This value exceeds the healthy maximum of 70. It has decreased from 90.40 (Mar 24) to 90.15, marking a decrease of 0.25.
- For Price / BV (X), as of Mar 25, the value is 0.43. This value is below the healthy minimum of 1. It has decreased from 0.54 (Mar 24) to 0.43, marking a decrease of 0.11.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.75. This value is below the healthy minimum of 1. It has decreased from 0.99 (Mar 24) to 0.75, marking a decrease of 0.24.
- For EarningsYield, as of Mar 25, the value is 0.13. This value is below the healthy minimum of 5. It has increased from 0.11 (Mar 24) to 0.13, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Nath Bio-Genes (India) Ltd:
- Net Profit Margin: 10.57%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 7.64% (Industry Average ROCE: 16.97%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 5.99% (Industry Average ROE: 15.87%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 4.63
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.96
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 7 (Industry average Stock P/E: 41.52)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.19
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 10.57%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Seeds/Tissue Culture/Bio Technology | Nath House, Aurangabad Maharashtra 431005 | investor@nathbiogenes.com http://www.nathbiogenes.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Satish Kagliwal | Managing Director |
| Mr. Madhukar Deshpande | Director |
| Ms. Ashu Jain | Director |
| Mrs. Jeevanlata Kagliwal | Director |
| Mr. Vadla Nagabhushanam | Director |
| Mr. Hitesh Purohit | Director |
| Mr. Akash Kagliwal | Director |
FAQ
What is the intrinsic value of Nath Bio-Genes (India) Ltd?
Nath Bio-Genes (India) Ltd's intrinsic value (as of 29 October 2025) is 130.81 which is 22.60% lower the current market price of 169.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 321 Cr. market cap, FY2025-2026 high/low of 239/138, reserves of ₹630 Cr, and liabilities of 1,017 Cr.
What is the Market Cap of Nath Bio-Genes (India) Ltd?
The Market Cap of Nath Bio-Genes (India) Ltd is 321 Cr..
What is the current Stock Price of Nath Bio-Genes (India) Ltd as on 29 October 2025?
The current stock price of Nath Bio-Genes (India) Ltd as on 29 October 2025 is 169.
What is the High / Low of Nath Bio-Genes (India) Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Nath Bio-Genes (India) Ltd stocks is 239/138.
What is the Stock P/E of Nath Bio-Genes (India) Ltd?
The Stock P/E of Nath Bio-Genes (India) Ltd is 7.00.
What is the Book Value of Nath Bio-Genes (India) Ltd?
The Book Value of Nath Bio-Genes (India) Ltd is 341.
What is the Dividend Yield of Nath Bio-Genes (India) Ltd?
The Dividend Yield of Nath Bio-Genes (India) Ltd is 1.18 %.
What is the ROCE of Nath Bio-Genes (India) Ltd?
The ROCE of Nath Bio-Genes (India) Ltd is 7.35 %.
What is the ROE of Nath Bio-Genes (India) Ltd?
The ROE of Nath Bio-Genes (India) Ltd is 6.77 %.
What is the Face Value of Nath Bio-Genes (India) Ltd?
The Face Value of Nath Bio-Genes (India) Ltd is 10.0.